Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05986682 · OUTCOME

Ophthalmology: Time to Resolution of Clinically Meaningful Ocular Toxicities - Best Corrected Visual Acuity

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Weeks
Interval / dispersion
Full Range
Time frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

Clinically Meaningful Event is defined as an event that is grade \>= 2 for which BLENREP administration is halted until the event resolves to grade \<= 1. Time to resolution is calculated for events that resolved. Unresolved events are those that had not returned to grade \<=1 at last contact due to either end of study or lost to ophthalmologic follow-up. There were 44 Resolved events for changes in Best Corrected Visual Acuity that were analyzed.

Groups in this outcome

Multiple Myeloma/Blenrep Participants

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Multiple Myeloma/Blenrep Participants30

Analysis denominator · Resolved Events

GroupSource count
Multiple Myeloma/Blenrep Participants44

Reported measurements

Source class 1
Values in Weeks · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants6Not reported353Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3
        upper Limit
        53
        value
        6
denom Units Selected
Resolved Events
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
  2. counts
    1. group Id
      OG000
      value
      44
    units
    Resolved Events
description
Clinically Meaningful Event is defined as an event that is grade \>= 2 for which BLENREP administration is halted until the event resolves to grade \<= 1. Time to resolution is calculated for events that resolved. Unresolved events are those that had not returned to grade \<=1 at last contact due to either end of study or lost to ophthalmologic follow-up. There were 44 Resolved events for changes in Best Corrected Visual Acuity that were analyzed.
dispersion Type
Full Range
groups
  1. description
    Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023
    id
    OG000
    title
    Multiple Myeloma/Blenrep Participants
param Type
MEDIAN
reporting Status
POSTED
time Frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
title
Ophthalmology: Time to Resolution of Clinically Meaningful Ocular Toxicities - Best Corrected Visual Acuity
type
POST_HOC
type Units Analyzed
Resolved Events
unit Of Measure
Weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice